Suppr超能文献

43例连续口服避孕药所致肝损伤患者的临床特征、实验室检查特点及预后,并对已发表报告进行简要综述

Clinical Features, Laboratory Characteristics and Outcome from Oral Contraceptives-induced Liver Injury in 43 Consecutive Patients and a Brief Review of Published Reports.

作者信息

Patil Mallikarjun, Devarbhavi Harshad, Mishra Amit, Pavan Kumar Y M, Dhali Gopal K, Chowdhury Abhijit

机构信息

Department of Gastroenterology and Hepatology, St. John's Medical College Hospital, Bangalore, India.

Department of Gastroenterology and Hepatology, Institute of Postgraduate Medical Education & Research, Kolkata, India.

出版信息

J Clin Exp Hepatol. 2024 May-Jun;14(3):101322. doi: 10.1016/j.jceh.2023.101322. Epub 2023 Dec 16.

Abstract

BACKGROUND

Hormonal oral contraceptive (OC) agents such as estrogen or progesterone, either as single agents or in combination, and a non-hormonal drug like ormeloxifene are used for various conditions. However, estrogen and progesterone-containing OC as well as ormeloxifene are seldom associated with hepatotoxicity. We prospectively studied the clinical, demographic, liver injury pattern, complications, and outcome of the hepatotoxicity from OC and ormeloxifene.

METHODS

We analyzed and compared the aforementioned characteristics among consecutive patients with OC and ormeloxifene-induced drug-induced liver injury (DILI) from two university hospitals in India. Cases fulfilling established DILI criteria and the Roussel Uclaf causality assessment method were identified and followed up until recovery/death.

RESULTS

We identified 43 (3.5%) amongst 1226 patients with DILI; 19 (44%) from estrogen and progesterone combination, 21 (49%) from progesterone monotherapy, and 3 (7%) due to ormeloxifene. Seven cases were identified from 1998 to 2014 and 36 cases from 2015 to 2023. All were due to oral tablets. The mean age was 36 years (range 21-75). Nineteen patients (44%) developed jaundice and 5 (11.6%) developed itching. The liver injury pattern was hepatocellular in 19 (44%), mixed in 13 (30%), and cholestatic in 11 (26%). Four patients (9%) died, three from acute liver failure and one due to acute on chronic liver failure. Liver biochemical tests normalized after a mean of 66 days after stopping the implicated agents. Contrastingly, literature search yielded 24 cases of progesterone DILI reported between 1962 and 2019 with no mortality.

CONCLUSION

In contrast to published literature on oral contraceptives, a majority of oral contraceptive-induced DILI in our series were from progesterone monotherapy and a smaller number with ormeloxifene, that often resulted in clinically significant jaundice or liver test abnormalities and rarely in fatality.

摘要

背景

激素口服避孕药(OC),如雌激素或孕激素,单独使用或联合使用,以及非激素药物奥莫昔芬可用于多种情况。然而,含雌激素和孕激素的OC以及奥莫昔芬很少与肝毒性相关。我们前瞻性地研究了OC和奥莫昔芬所致肝毒性的临床、人口统计学、肝损伤模式、并发症及转归。

方法

我们分析并比较了印度两家大学医院连续的OC和奥莫昔芬所致药物性肝损伤(DILI)患者的上述特征。确定符合既定DILI标准和罗塞尔 - 优克福因果关系评估方法的病例,并随访至康复/死亡。

结果

在1226例DILI患者中,我们识别出43例(3.5%);19例(44%)由雌激素和孕激素联合使用引起,21例(49%)由孕激素单药治疗引起,3例(7%)由奥莫昔芬引起。1998年至2014年识别出7例,2015年至2023年识别出36例。均由口服片剂引起。平均年龄为36岁(范围21 - 75岁)。19例(44%)患者出现黄疸,5例(11.6%)出现瘙痒。肝损伤模式为肝细胞型19例(44%),混合型13例(30%),胆汁淤积型11例(26%)。4例(9%)患者死亡,3例死于急性肝衰竭,1例死于慢性肝衰竭急性发作。停用相关药物后,肝脏生化检查平均在66天后恢复正常。相比之下,文献检索发现1962年至2019年间报告了24例孕激素所致DILI,无死亡病例。

结论

与关于口服避孕药的已发表文献相比,我们系列中大多数口服避孕药所致DILI来自孕激素单药治疗,少数由奥莫昔芬引起,常导致临床上显著的黄疸或肝功能检查异常,很少导致死亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f675/10818198/f5d5d6082b0b/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验